Drug Prices Cut Across Major Therapeutic Categories in 2025
U.S. prescription drug spending declined in early 2025 as new federal price controls, IRA-mandated negotiations, and insulin caps took effect. The Centers for Medicare and Medicaid Services reported that out-of-pocket costs for covered Part D and Medicare Advantage drugs fell by double digits in the first quarter compared with 2024, with insulin products seeing some of the steepest reductions. According to the latest available public data, the average negotiated price for the first batch of Medicare-selected high-cost drugs dropped more than 30 percent from their pre-negotiation list prices, and subsequent batches continued the trend. Insulin products, including branded and biosimilar versions, now face a $35 monthly cap under Medicare, a policy that directly contributed to the drug prices cut seen in recent government reports. The Inflation Reduction Act remains the primary legislative driver, requiring the Department of Health and Human Services to negotiate prices for select high-expenditure drugs and to enforce inflation rebates if manufacturers raise prices faster than inflation. For a broader view of the policy framework and the specific drugs selected for negotiation, see the official CMS guidance on Medicare Drug Price Negotiation.
Private insurers and pharmacy benefit managers also adjusted formularies and rebate structures in response to the new regulatory environment. Major insurers including UnitedHealth Group, CVS Health, and Elevance Health reported lower net costs for insulin and several chronic disease therapies, passing savings to consumers through reduced copays. The trend is especially visible in the commercial segment, where employer-sponsored plans increasingly adopted $35 insulin caps even before the Medicare mandate, following state-level laws in states such as Colorado, Illinois, and Virginia. As a result, the average cash price for a month's supply of popular insulins fell below $100 at many retail pharmacies in 2025, according to data compiled from GoodRx price tracking and employer benefit surveys. The combined effect of federal negotiation, state caps, and payer pressure created a measurable drug prices cut across multiple therapy areas, including diabetes, hepatitis C, and certain oncology drugs. For an analysis of how commercial plans are implementing these savings, see the Forbes coverage on employer health plan reforms and prescription drug costs.
Medicare Negotiation Results and Manufacturer Responses
The first two rounds of Medicare Drug Price Negotiation produced final negotiated prices for dozens of high-spend drugs, with manufacturers including Eli Lilly, Novo Nordisk, Boehringer Ingelheim, and AstraZeneca agreeing to discounts in exchange for continued Medicare coverage. The negotiated prices, which CMS finalized in 2024 and began enforcing in 2025, apply to drugs such as insulin glargine, Januvia, Xarelto, and several cancer therapies, with savings projected to total tens of billions of dollars over the decade-long negotiation window. Manufacturers that refuse to participate face an excise tax equal to 95 percent of the product's previous year sales, a penalty that incentivized participation across the industry. The resulting drug prices cut is expected to reduce federal spending on Medicare Part D and Medicare Advantage prescription drug benefits by billions annually, according to the Congressional Budget Office score of the IRA provisions. For the full list of negotiated drugs and final prices, see the official CMS Medicare Drug Price Negotiation page.
Pharmaceutical company earnings calls in early 2025 reflected the impact of the negotiated prices, with several firms revising full-year revenue guidance downward for affected products while highlighting pipeline investments and international market growth. Novo Nordisk, for example, noted that the Medicare insulin cap and negotiated discounts in other markets would weigh on U.S. insulin revenue but expected volume growth in global markets to partially offset the impact. Eli Lilly reported similar dynamics for its diabetes and obesity drugs, noting that list price reductions in the U.S. were balanced by strong demand and payer contracts in Europe and Asia. The company also pointed to new formulations and delivery devices that maintain margins despite the lower net prices. These manufacturer responses